1 Amend 17 Cal. Code of Regs. section 100070 to read:

§ 100070. SCRO Committee Review and Notification.

- (a) CIRM-funded research involving the procurement or use of human oocytes <u>or the</u> <u>creation of human gametes</u> may not commence without SCRO committee review and approval in writing. <u>If CIRM-funded research involves the procurement of human oocytes from a living donor For such SCRO committee review and approval, a member of the committee with expertise in assisted reproduction shall be present. The designated SCRO committee may require that modification be made to proposed research or documentation of compliance with the requirements of subdivision (a)(3) of this regulation as a condition of granting its approval. At a minimum, the SCRO committee shall require the investigator to:</u>
 - (1) Provide an acceptable scientific rationale for the need to <u>procure or</u> use <u>human</u> oocytes <u>or create human gametes</u>. <u>In the case of human oocyte procurement</u>, <u>including</u> a justification for the number needed. If SCNT is proposed a justification for SCNT shall be provided.
 - (2) Demonstrate experience, expertise or training in derivation or culture of human or nonhuman stem cell lines.
 - (3) Provide documentation of compliance with any required review of the proposed research by an IRB, Institutional Animal Care and Use Committee (IACUC), Institutional Bioethics Committee (IBC), or other mandated review.
 - (b) CIRM-funded research involving <u>procurement</u>, <u>creation or</u> use of human <u>blastocysts</u> <u>or</u> embryos may not commence without SCRO committee review and approval in writing. The designated SCRO committee may require that modification be made to proposed research or

1	documentation of compliance with the requirements of subdivision (b)(3) of this regulation as a
2	condition of granting its approval. At a minimum, the SCRO committee shall require the
3	investigator to:
4	(1) Provide an acceptable scientific rationale for the need to <u>create or</u> use
5	blastocysts or embryos including a justification for the number needed.
6	(2) Demonstrate experience, expertise or training in derivation or culture of
7	human or nonhuman stem cell lines.
8	(3) Provide documentation of compliance with any required review of the
9	proposed research by an IRB, Institutional Animal Care and Use Committee (IACUC),
10	Institutional Bioethics Committee (IBC), or other mandated review.
11	(c) CIRM-funded research with the aim to derive or create a covered stem cell line from
12	human gametes, embryos or products of SCNT involving a human donor nucleus may not
13	commence without SCRO committee review and approval in writing. human subjects research,
14	as defined by Title 45 Code of Federal Regulations, Part 46 (Protection of Human Subjects),
15	revised June 23, 2005, and California Health and Safety Code section 24173 with the aim to
16	create, from sources other than human gametes, blastocysts or embryos, or use a covered stem

cell line may not commence with out written notification of the SCRO committee. Research may

include animal assays to evaluate pluripotency; however, subsequent introduction of derived

covered stem cell lines in non-human animals shall be reviewed in accordance with section (e).

The designated SCRO committee may require that modification be made to proposed research or

documentation of compliance with the requirements of subdivision (c)(4) of this regulation as a

condition of granting its approval. At a minimum, the SCRO committee shall require the

17

18

19

20

21

22

1	investigator to:
2	(1) Provide an acceptable scientific rationale for the need to derive a covered
3	stem cell line.
4	(2) If SCNT is proposed as a route to generating human stem cell lines, a
5	justification for SCNT shall be provided.
6	(3)(1) Demonstrate experience, expertise or training in derivation or culture of
7	human or nonhuman stem cell lines.
8	(4)(2) Provide documentation of compliance with any required review of the
9	proposed research by an IRB, Institutional Bioethics Committee (IBC), or other
10	mandated review.
11	(5)(3) Document how stem cell lines will be characterized, validated, stored, and
12	distributed to ensure that the confidentiality of the donor(s) is protected.
13	(d) CIRM-funded purely in vitro research utilizing covered stem cell lines or the
14	reprogramming of human somatic cells with the aim to derive or create a covered stem cell line
15	may not commence without written notification to the designated SCRO committee. with the aim
16	to create or use a covered stem cell line from non-identifiable cells may not commence with out
17	written notification of the SCRO committee. A statement from the designated institutional
18	official (Title 17, California Code of Regulations, section 100040, subdivision (b)(1)) may be
19	provided in lieu of SCRO committee notification if human somatic cells conform to the
20	requirements of Title 17, California Code of Regulations, section 100080, subdivision (a)(3); or
21	the covered stem cell line(s) are recognized by an authorized authority. At a minimum the
22	statement shall certify the:
	10/30/09 3 100070 Amendments; 2 nd Public Notice

1	(1) Human somatic cells conform to the requirements of Section 100080(a)(3); or
2	(2) The covered stem cell lines are recognized by an authorized authority.
3 4	In addition, the institutional official shall submit documentation of any required review of
5	the proposed research by an IRB, IACUC, IBC, or other mandated review.
6	
7	Research may include animal assays to evaluate pluripotency; however, subsequent
8	introduction of derived covered stem cell lines in non-human animals shall be reviewed in
9	accordance with subdivision (e) of this regulation. At a minimum, the notification shall:
10	(1) Provide assurance that all covered stem cell lines have been acceptably
11	derived.
12	(2) Provide documentation of compliance with any required review of the
13	proposed research by an IRB, IACUC, IBC, or other mandated review.
14	(e) CIRM-funded research introducing covered stem cell lines into non-human animals
15	or introducing neural-progenitor cells into the brain of non-human animals at any state of
16	embryonic, fetal, or postnatal development may not commence without SCRO committee review
17	and approval in writing. The designated SCRO committee may require that modification be
18	made to proposed research or documentation of compliance with the requirements of subdivision
19	(e)(3) of this regulation as a condition of granting its approval. The SCRO committee may
20	establish guidelines and procedures for expedited review of animal research so that review by the
21	entire SCRO committee is not required. At a minimum, the SCRO committee shall require the
22	investigator to:
23	(1) Provide an acceptable scientific rationale for introducing stem cells into non-
	10/30/09 4 100070 Amendments; 2 nd Public Notice

1	human animals.
2	(2) Provide assurance that all covered stem cell lines have been acceptably
3	derived.
4	(3) Evaluate the probable pattern and effects of differentiation and integration of
5	the human cells into the nonhuman animal tissues.
6	(4) Provide documentation of compliance with any required review of the
7	proposed research by an IRB, IACUC, IBC, or other mandated review.
8	(f) CIRM-funded research introducing stem cells from covered stem cell lines into a live
9	born human may not commence without SCRO committee review and approval in writing. The
10	designated SCRO committee may require that modification be made to proposed research or
11	documentation of compliance with the requirements of subdivision (f)(4) of this regulation as a
12	condition of granting its approval. At a minimum, the SCRO committee shall require the
13	investigator to:
14	(1) Provide an acceptable scientific for rationale introducing stem cells into
15	humans.
16	(2) Provide assurance that all covered stem cell lines have been acceptably
17	derived.
18	(3) Evaluate the probable pattern and effects of differentiation and integration of
19	the human cells into the human tissues.
20	(4) Provide documentation of compliance with any required review of the
21	proposed research by an IRB, IACUC, IBC, or other mandated review.
22	(g) In cases where SCRO committee approval is required, a SCRO committee shall
	10/30/09 5 100070 Amendments; 2 nd Public Notice

- 1 notify investigators in writing of its decision to approve or disapprove the proposed research
- 2 activity, or of modifications required to secure SCRO committee approval of the research
- 3 activity. If the SCRO committee decides to disapprove a research activity, it shall include in its
- 4 written notification a statement of the reasons for its decision and give the investigator an
- 5 opportunity to respond in person or in writing.
- 6 (h) SCRO committee approvals shall be reviewed no less frequently than once per year.
- 7 The renewal review shall confirm compliance with all applicable rules and regulations. The
- 8 SCRO committee may establish guidelines and procedures for expedited review of renewals so
- 9 that review by the entire SCRO committee is not required.
- Note: Authority cited: Article XXXV, California Constitution; Section 125290.40(j), Health and

6

11 Safety Code. Reference: Sections 125290.40, 125290.55, Health and Safety Code.